Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing

NCT02604511 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
31
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Dana-Farber Cancer Institute

Collaborators